1.2 Million Dollars Awarded to Institute for Myeloma and Bone Cancer Research
FJC, a foundation of philanthropic donor-advised funds and the Myeloma Research Foundation are the latest major donors to the "Cure Myeloma Project", an ongoing research initiative at the Institute for Myeloma and Bone Cancer Research, (IMBCR), in Los Angeles, CA.
IMBCR's "Cure Myeloma Project" is the nation's foremost effort to find a cure for multiple myeloma, a blood cancer that resides in bone marrow. Led by premier scientists in the world of myeloma research, James R. Berenson, M.D., Haiming Chen, M.D., Ph.D. and Zhi-Wei Li, Ph.D., this multi-phase research project's overall goal is to specifically target myeloma cells while leaving surrounding healthy cells untouched.
Over the past five years, researchers and scientists at IMBCR have been responsible for creating many of the novel therapeutics currently used to extend the quality of life and lifespan of myeloma patients throughout the world.
About Multiple Myeloma and Blood Cancers: The American Cancer Society predicts that over 80,000 people are currently living with myeloma in the US and over 20,000 new cases are diagnosed each year. Approximately 10,000 people die each year from multiple myeloma. The Leukemia & Lymphoma Society estimates that 894,543 people in the US are presently battling blood cancers that include leukemia, lymphoma and myeloma. Blood cancers are the second most fatal form of cancer, second only to lung cancer.
About IMBCR: Headquartered in Los Angeles, California, IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma and other forms of blood cancer. IMBCR research findings have been presented at numerous scientific meetings throughout the world and its research has been published in most major oncology journals. www.imbcr.org
IMBCR's "Cure Myeloma Project" is the nation's foremost effort to find a cure for multiple myeloma, a blood cancer that resides in bone marrow. Led by premier scientists in the world of myeloma research, James R. Berenson, M.D., Haiming Chen, M.D., Ph.D. and Zhi-Wei Li, Ph.D., this multi-phase research project's overall goal is to specifically target myeloma cells while leaving surrounding healthy cells untouched.
Over the past five years, researchers and scientists at IMBCR have been responsible for creating many of the novel therapeutics currently used to extend the quality of life and lifespan of myeloma patients throughout the world.
About Multiple Myeloma and Blood Cancers: The American Cancer Society predicts that over 80,000 people are currently living with myeloma in the US and over 20,000 new cases are diagnosed each year. Approximately 10,000 people die each year from multiple myeloma. The Leukemia & Lymphoma Society estimates that 894,543 people in the US are presently battling blood cancers that include leukemia, lymphoma and myeloma. Blood cancers are the second most fatal form of cancer, second only to lung cancer.
About IMBCR: Headquartered in Los Angeles, California, IMBCR is the only independent non-profit cancer research institute working to find improved treatment, and ultimately a cure for multiple myeloma and other forms of blood cancer. IMBCR research findings have been presented at numerous scientific meetings throughout the world and its research has been published in most major oncology journals. www.imbcr.org
posted by gwg at 4:52 PM
0 Comments:
Post a Comment
<< Home